Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
303-03-008 ISMRM Abstract

Classification of Glioma Subtypes Using 7T MR Spectroscopic Imaging

Primary: Neuro - Tumors
Secondary: Contrast Mechanisms - Spectroscopy
303-03-008 · Advanced Tumor Imaging: Bridging Research and Clinical Practice · Monday, 11 May, 4:10 PM–6:00 PM · Auditorium 1
Keywords: 3D magnetic resonance spectroscopic imaging Glioma classification Adult-type diffuse glioma Ultra high field MRI
Accepted
Sara Huskic 1, Philipp Lazen1, Thomas Roetzer-Pejrimovsky1,2, Rebeka Rumbak1,3, Ahmet Azgın1, Sagar Acharya1,4, Stanislav Motyka1,4, Bernhard Strasser1, Lukas Hingerl1, Anita Kloss-Brandstätter5, Matthias Preusser6, Johannes Leitner1, Juliane Hennenberg1, Karl Rössler1, Guenther Grabner7, Wolfgang Bogner1,4, Georg Widhalm1, Gilbert Hangel1,4
1Medical University of Vienna, Vienna, Austria
2Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria
3Department of Neurology, Medical University of Vienna, Vienna, Austria
4Christian Doppler Laboratory for MR Imaging Biomarkers (BIOMAK), Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
5Department of Engineering & IT, Carinthia University of Applied Sciences, Villach, Austria, Austria
6Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
7Department of Medical Engineering, Carinthia University of Applied Sciences, Klagenfurt, Austria
Presenting Author: Sara Huskic

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of Brain and Other CNS Tumors. Curr Neurol Neurosci Rep. 2021;21(12):68. doi:10.1007/s11910-021-01152-9 [doi]
2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106 [doi]
3. Johnson DR, Giannini C, Vaubel RA, et al. A Radiologist’s Guide to the 2021 WHO Central Nervous System Tumor Classification: Part I—Key Concepts and the Spectrum of Diffuse Gliomas. Radiology. 2022;304(3):494-508. doi:10.1148/radiol.213063 [doi]
4. Karschnia P, Dietrich J, Bruno F, et al. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement ( low-grade appearance ): a report of the RANO resect group. Neuro-Oncol. 2024;26(1):166-177. doi:10.1093/neuonc/noad160 [doi]
5. Johnson DR, Giannini C, Vaubel RA, et al. A Radiologist’s Guide to the 2021 WHO Central Nervous System Tumor Classification: Part I—Key Concepts and the Spectrum of Diffuse Gliomas. Radiology. 2022;304(3):494-508. doi:10.1148/radiol.213063 [doi]
6. Hassannejad E, Mohammadifard M, Payandeh A, et al. Correlation of ADC values of adult brain tumors with the diagnosis and pathological grade: A cross‐sectional multicenter study. Health Sci Rep. 2024;7(6):e2110. doi:10.1002/hsr2.2110 [doi]
7. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624-629. doi:10.1038/nm.2682 [doi]
8. Miyata S, Tominaga K, Sakashita E, et al. Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of β-oxidation Due to Carnitine Deficiency. Sci Rep. 2019;9(1):9787. doi:10.1038/s41598-019-46217-5 [doi]
9. Zhou L, Wang Z, Hu C, et al. Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation. J Proteome Res. 2019;18(3):960-969. doi:10.1021/acs.jproteome.8b00663 [doi]
10. Hingerl L, Strasser B, Moser P, et al. Clinical High-Resolution 3D-MR Spectroscopic Imaging of the Human Brain at 7 T. Invest Radiol. 2020;55(4):239-248. doi:10.1097/RLI.0000000000000626 [doi]
11. Provencher SW. Automatic quantitation of localized in vivo1 H spectra with LCModel. NMR Biomed. 2001;14(4):260-264. doi:10.1002/nbm.698 [doi]
12. Hattingen E, Raab P, Franz K, Zanella FE, Lanfermann H, Pilatus U. Myo ‐Inositol: a marker of reactive astrogliosis in glial tumors? NMR Biomed. 2008;21(3):233-241. doi:10.1002/nbm.1186 [doi]
13. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol. 2000;21(9):1645-1649. PMID: 11039343 [pmid]
14. Zhu Z, Du S, Du Y, Ren J, Ying G, Yan Z. Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. J Neurochem. 2018;144(1):93-104. doi:10.1111/jnc.14250 [doi]
15. Tang X, Fu X, Liu Y, Yu D, Cai SJ, Yang C. Blockade of Glutathione Metabolism in IDH1-Mutated Glioma. Mol Cancer Ther. 2020;19(1):221-230. doi:10.1158/1535-7163.MCT-19-0103 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/303-03-008